Treatment of advanced ovarian cancer: A randomised trial comparing adriamycin or 4′epi-adriamycin in combination with cisplatin and cyclophosphamide

Abstract

Fifty‐one patients with ovarian cancer were entered in a randomised trial comparing treatment with cisplatin + adriamycin + cyclophosphamide (PAC) to cisplatin + 4′epi‐adriamycin + cyclophosphamide (PEC). Complete response rates for the two treatment arms were similar (9/27 PAC, 14/24 PEC). Patients with < 2 cm residual disease had significantly higher rate of complete remission than those with > 2 cm residual disease. Cardiotoxicity was significantly less in the PEC‐treated group (0/24) as compared with the PAC‐treated group (6/27, χ² = 4.09, p < 0.05).